Top

Published in:

Open Access 01-12-2012 | Special Situations in the Management of Hypertension (T Kotchen, Section Editor)

Blood Pressure J-Curve: Current Concepts

Authors: Maciej Banach, Wilbert S. Aronow

Published in: Current Hypertension Reports | Issue 6/2012

Abstract

The blood pressure (BP) J-curve debate started in 1979, and we still cannot definitively answer all the questions. However, available studies of antihypertensive treatment provide strong evidence for J-shaped relationships between both diastolic and systolic BP and main outcomes in the general population of hypertensive patients, as well as in high-risk populations, including subjects with coronary artery disease, diabetes mellitus, left ventricular hypertrophy, and elderly patients. However, further studies are still necessary in order to clarify this issue. This is connected to the fact that most available studies were observational, and randomized trials did not have or lost their statistical power and were inconclusive. Perhaps only the Systolic Blood Pressure Intervention Trial (SPRINT) and Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives (ESH-CHL-SHOT) will be able to finally answer all the questions. According to the current state of knowledge, it seems reasonable to suggest lowering BP to values within the 130–139/80–85 mmHg range, possibly close to the lower values in this range, in all hypertensive patients and to be very careful with further BP level reductions, especially in high-risk hypertensive patients.

Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e21–e181.PubMedCrossRef

Banach M, Aronow WS. Hypertension therapy in the older adults-do we know the answers to all the questions? The status after publication of the ACCF/AHA 2011 expert consensus document on hypertension in the elderly. J Hum Hypertens 2012; DOI: 10.1038/jhh.2012.3.

Chockalingam A, Campbell NR, Fodor JG. Worldwide epidemic of hypertension. Can J Cardiol. 2006;22:553–5.PubMedCrossRef

Bielecka-Dabrowa A, Aronow WS, Rysz J, Banach M. The Rise and Fall of Hypertension: Lessons Learned from Eastern Europe. Curr Cardiovasc Risk Rep. 2011;5:174–9.PubMedCrossRef

Barylski M, Małyszko J, Rysz J, Myśliwiec M, Banach M. Lipids, blood pressure, kidney—what was new in 2011? Arch Med Sci. 2011;7(6):1055–66.PubMedCrossRef

Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clément D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, Van Zwieten PA, Viigimaa M, Zanchetti A. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121–58.PubMedCrossRef

Banach M, Kjeldsen SE, Narkiewicz K. Editorial. Controversies in hypertension treatment. Curr Vasc Pharmacol. 2010;8:731–2.PubMedCrossRef

Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, Kolloch R, Benetos A, Pepine CJ. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med. 2006;144:884–93.PubMed

Reboldi G, Gentile G, Manfreda VM, Angeli F, Verdecchia P. Tight blood pressure control in diabetes: evidence-based review of treatment targets in patients with diabetes. Curr Cardiol Rep. 2012;14:89–96.PubMedCrossRef

10.

Banach M, Michalska M, Kjeldsen SE, Małyszko J, Mikhailidis DP, Rysz J. What should be the optimal levels of blood pressure: Does the J-curve phenomenon really exist? Expert Opin Pharmacother. 2011;12(12):1835–44.PubMedCrossRef

11.

Gluba A, Bielecka A, Mikhailidis DP, Wong ND, Franklin SS, Rysz J, Banach M. An update on biomarkers of heart failure in hypertensive patients. J Hypertens. 2012;30:1681–9.PubMedCrossRef

12.

Kaplan NM. The diastolic J curve: alive and threatening. Hypertension. 2011;58(5):751–3.PubMedCrossRef

13.

Panjrath GS, Chaudhari S, Messerli FH. The J-point phenomenon in aggressive therapy of hypertension: new insights. Curr Atheroscler Rep. 2012;14(2):124–9.PubMedCrossRef

14.

Stewart IM. Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. Lancet. 1979;1:861–5.PubMedCrossRef

15.

Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet. 1987;1(8533):581–4.PubMedCrossRef

16.

D'Agostino RB, Belanger AJ, Kannel WB, Cruickshank JM. Relation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction: the Framingham Study. BMJ. 1991;303:385–9.PubMedCrossRef

17.

Dudenbostel T, Oparil S. J curve in hypertension. Curr Cardiovasc Risk Rep. 2012;6:281–90.CrossRef

18.

Polese A, De Cesare N, Montorsi P, Fabbiocchi F, Guazzi M, Loaldi A, Guazzi MD. Upward shift of the lower range of coronary flow autoregulation in hypertensive patients with hypertrophy of the left ventricle. Circulation. 1991;83:845–53.PubMedCrossRef

19.

Okoński P, Banach M, Rysz J, Barylski M, Irzmański R, Piechota M, Zasłonka J. L-arginine improves hemodynamic function and coronary flow in an experimental model of ischemia-reperfusion injury. Ann Transplant. 2006;11(1):28–34.PubMed

20.

Ma J, Qian J, Ge J, Zeng X, Sun A, Chang S, Chen Z, Zou Y. Changes in left ventricular ejection fraction and coronary flow reserve after coronary microembolization. Arch Med Sci. 2012;8(1):63–9.PubMedCrossRef

21.

Williams B, Lindholm LH, Sever P. Systolic pressure is all that matters. Lancet. 2008;371:2219–21.PubMedCrossRef

22.

Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical appraisal. J Hypertens. 2009;27:923–34.PubMedCrossRef

23.

Marschner IC, Simes RJ, Keech A. Biases in the identification of risk factor thresholds and J-curves. Am J Epidemiol. 2007;166:824–31.PubMedCrossRef

24.

Kalantar-Zadeh K, Block G, Horwich T, Fonarow G. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol. 2004;43:1439–44.PubMedCrossRef

25.

Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, DiAngelantonio E, et al. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215–22.PubMedCrossRef

26.

Hansson L for the BBB Study Group. The BBB Study: The effect of intensified antihypertensive treatment on the level of blood pressure, side effects, morbidity and mortality in “well-treated” hypertensive patients. Blood Press. 1994;3:248–54.CrossRef

27.

Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351(9118):1755–62.PubMedCrossRef

28.

Cruickshank JM. Hypertension Optimal Treatment (HOT) trial. Lancet. 1998;352:573–4.PubMedCrossRef

29.

Hedner T, Oparil S, Narkiewicz K, Kjeldsen SE. The J-curve phenomenon revisited. Blood Press. 2009;18:168–70.PubMedCrossRef

30.

Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022–3.PubMedCrossRef

31.

Messerli FH, Mancia G, Weber MA, Kjeldsen SE, Holzhauer B, Hua TA, et al. Low blood pressure is associated with increased cardiovascular morbidity (J-shaped curve) in treated hypertensive patients with increased cardiovascular risk: The VALUE Randomized Trial. J Am Coll Cardiol. 2009;53(Suppl A):A46.

32.

Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, Schumacher H, Weber M, Böhm M, Williams B, Pogue J, Koon T, Yusuf S. ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens. 2009;27:1360–9.PubMedCrossRef

33.

Mancia G, Schumacher H, Redon J, Verdecchia P, Schmieder R, Jennings G, et al. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in ONTARGET. Circulation. 2011;124:1727–36.PubMedCrossRef

34.

Banach M, Rysz J. Current problems in hypertension and nephrology. Expert Opin Pharmacother. 2010;11:2575–8.PubMedCrossRef

35.

Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A, Mureddu G, Pede S, Maggioni AP, Lucci D, Reboldi G. Cardio-Sis investigators. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet. 2009;374:525–33.PubMedCrossRef

36.

Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW. INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805–16.PubMedCrossRef

37.

Bangalore S, Messerli FH, Wun C, Zuckerman AL, DeMicco D, Kostis JB, LaRosa JC. J-curve revisited: an analysis of the Treating to New Targets (TNT) Trial. J Am Coll Cardiol. 2009;53:A217.

38.

Bangalore S, Messerli FH, Wun CC, Zuckerman AL, DeMicco D, Kostis JB, LaRosa JC. Treating to New Targets Steering Committee and Investigators. J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J. 2010;31:2897–908.PubMedCrossRef

39.

•• Bangalore S, Qin J, Sloan S, Murphy SA, Cannon CP. PROVE IT-TIMI 22 Trial Investigators. What is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial. Circulation. 2010;122:2142–51. Very important study in patients with acute coronary syndromes suggesting that low BP, especially <110/70 mmHg, may be very harmful for this group of patients. PubMedCrossRef

40.

•• Dorresteijn JA, van der Graaf Y, Spiering W, Grobbee DE, Bots ML, Visseren FL. Secondary Manifestations of Arterial Disease Study Group. Relation between blood pressure and vascular events and mortality in patients with manifest vascular disease: J-curve revisited. Hypertension. 2012;59:14–21. One of the most current trials (SMART) in patients with symptomatic vascular disease, which confirmed that a J-curve relationship (increased risk of CV events) was observed above and below the nadir of 143/82 mmHg. A similar nonlinear relationship was also found for DBP and all-cause mortality..PubMedCrossRef

41.

Bangalore S, Kumar S, Volodarskiy A, Messerli FH. Blood pressure targets in patients with coronary artery disease: observations from traditional and Bayesian random effects meta-analysis of randomised trials. Heart 2012; (in press).

42.

Tryniszewski W, Kuśmierczyk J, Maziarz Z, Goś R, Mikhailidis DP, Banach M, Rysz J, Pesudovs K. Correlation of the severity of diabetic retinopathy and the heart muscle perfusion in patients with type 2 diabetes. J Diabetes Complicat. 2011;25(4):253–7.PubMedCrossRef

43.

•• Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, Pepine CJ. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61–8. A retrospective analysis of the INVEST study, which revealed that this risk of CV events was also observed in diabetic patients with SBP below 115 mmHg. PubMedCrossRef

44.

•• The ACCORD Study Group. Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. N Engl J Med. 2010;362:1575–85. One of the most anticipated trials, which could have finally confirmed the J-curve relationship in diabetic patients. However, due to some limitations the interpretation of the study is not unequivocal.CrossRef

45.

Nilsson PM. ACCORD and risk-factor control in type 2 diabetes. N Engl J Med. 2010;362:1628–30.PubMedCrossRef

46.

Cooper-DeHoff RM, Egelund EF, Pepine CJ. Blood pressure lowering in patients with diabetes—one level might not fit all. Nat Rev Cardiol. 2011;8:42–9.PubMedCrossRef

47.

Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Pohl M, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ, Collaborative Study Group. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol. 2005;16:2170–9.PubMedCrossRef

48.

Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61:1086–97.PubMedCrossRef

49.

Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, Fagard R, Verdecchia P, Weber M, Böhm M, Williams B, Yusoff K, Teo K, Yusuf S. ONTARGET Investigators. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol. 2012;59:74–83.PubMedCrossRef

50.

• Vamos EP, Harris M, Millett C, Pape UJ, Khunti K, Curcin V, Molokhia M, Majeed A. Association of systolic and diastolic blood pressure and all cause mortality in people with newly diagnosed type 2 diabetes: retrospective cohort study. BMJ. 2012;345:e5567. One of the most recent trials investigating the J-shaped relationship in DM patients. Analysing 126,092 adult patients from the United Kingdom General Practice Research Database, it showed that intensive BP lowering (<130/80) was associated with an increased risk of all-cause mortality. PubMedCrossRef

51.

Banach M, Aronow WS. Should we have any doubts about hypertension therapy in elderly patients?: ACCF/AHA 2011 expert consensus document on hypertension in the elderly. Pol Arch Med Wewn. 2011;121:253–7.

52.

Global Health Risks. Mortality and burden of disease attributable to selected major risks. World Health Organization 2009:

53.

Athyros VG, Giouleme O, Ganotakis ES, Elisaf M, Tziomalos K, Vassiliadis T, Liberopoulos EN, Theocharidou E, Karagiannis A, Mikhailidis DP. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci. 2011;7:796–805.PubMedCrossRef

54.

Aronow WS, Banach M. Ten most important things to learn from the ACCF/AHA 2011 expert consensus document on hypertension in the elderly. Blood Press. 2012;21:3–5.PubMedCrossRef

55.

Vokó Z, Bots ML, Hofman A, Koudstaal PJ, Witteman JC, Breteler MM. J-shaped relation between blood pressure and stroke in treated hypertensives. Hypertension. 1999;34:1181–5.PubMedCrossRef

56.

SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in The Elderly Program. JAMA. 1991;265:3255–64.CrossRef

57.

Pastor-Barriuso R, Banegas JR, Damian J, Appel LJ, Guallar E. Systolic blood pressure, diastolic blood pressure, and pulse pressure: an evaluation of their joint effect on mortality. Ann Intern Med. 2003;139:731–9.PubMed

58.

Staessen JA, Thijisq L, Fagard R, Celis H, Birkenhäger WH, Bulpitt CJ, de Leeuw PW, Fletcher AE, Forette F, Leonetti G, McCormack P, Nachev C, O'Brien E, Rodicio JL, Rosenfeld J, Sarti C, Tuomilehto J, Webster J, Yodfat Y, Zanchetti A. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens. 2004;22:847–57.PubMedCrossRef

59.

Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80years of age or older. N Engl J Med. 2008;358:1887–98.PubMedCrossRef

60.

JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res. 2008;31:2115–27.CrossRef

61.

Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K, Imai Y, Kikuchi K, Ito S, Eto T, Kimura G, Imaizumi T, Takishita S, Ueshima H. Valsartan in Elderly Isolated Systolic Hypertension Study Group. Target blood pressure for treatment of isolated systolic hypertension in the elderly: Valsartan in Elderly Isolated Systolic Hypertension Study. Hypertension. 2010;56:196–202.PubMedCrossRef

62.

Oates DJ, Berlowitz DR, Glickman ME, Silliman RA, Borzecki AM. Blood pressure and survival in the oldest old. J Am Geriatr Soc. 2007;55(3):383–8.PubMedCrossRef

63.

• Denardo SJ, Gong Y, Nichols WW, et al. Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST Substudy. Am J Med. 2010;123(8):719–26. A subanalysis of the INVEST trial on 2,180 old (>80 years) participants, which confirmed age-dependent J-shaped relationships between on-treatment SBP (nadir: 110-140 mmHg) and DBP (nadir: 70-75 mmHg) and the primary outcome (all-cause mortality, nonfatal MI or nonfatal stroke). PubMedCrossRef

64.

Ogihara T, Matsuoka H, Rakugi H. Practitioner's trial on the efficacy of antihypertensive treatment in elderly patients with hypertension II (PATE-hypertension II study) in Japan. Geriatr Gerontol Int. 2011;11(4):414–21.PubMedCrossRef

65.

• Okin PM, Hille DA, Kjeldsen SE, Dahlöf B, Devereux RB. Impact of lower achieved blood pressure on outcomes in hypertensive patients. J Hypertens. 2012;30:802–10. A subanalysis of LIFE study, where the authors found that SBP ≤130 mmHg was not associated with lower CV risk (in comparison to the group with SBP of 131 to 141 mmHg) and was associated with a significantly increased (29%) risk of death and a trend towards increased CV mortality. PubMedCrossRef

66.

• Banach M, Bhatia V, Feller MA, Mujib M, Desai RV, Ahmed MI, Guichard JL, Aban I, Love TE, Aronow WS, White M, Deedwania P, Fonarow G, Ahmed A. Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure. Am J Cardiol. 2011;107:1208–14. This is one of the few studies suggesting a J-shape relationship while lowering SBP below 120 mmHg in patients with chronic heart failure. PubMedCrossRef

67.

Desai RV, Banach M, Ahmed MI, Mujib M, Aban I, Love TE, White M, Fonarow G, Deedwania P, Aronow WS, Ahmed A. Impact of baseline systolic blood pressure on long-term outcomes in patients with advanced chronic systolic heart failure (insights from the BEST trial). Am J Cardiol. 2010;106(2):221–7.PubMedCrossRef

68.

Norris K, Bourgoigne J, Gassman J, Hebert L, et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension AASK (Trial). Am J Kidney Dis. 2006;48:739–51.PubMedCrossRef

69.

Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–60.PubMedCrossRef

70.

Aronow WS. What should the optimal blood pressure goal be in patients with diabetes mellitus or chronic kidney disease? Arch Med Sci. 2012;8:399–402.PubMedCrossRef

71.

Agarwal R. Blood pressure components and the risk for end-stage renal disease and death in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(4):830–7.PubMedCrossRef

72.

Piotrowski G, Banach M, Gerdts E, Mikhailidis DP, Hannam S, Gawor R, Stasiak A, Rysz J, Gawor Z. Left atrial size in hypertension and stroke. J Hypertens. 2011;29:1988–93.PubMedCrossRef

73.

Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:1665–83.CrossRef

74.

• Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives (ESH-CHL-SHOT). ClinicalTrials.gov Identifier: NCT01563731. The first study that aimed to investigate the optimal blood pressure levels in patients after stroke/TIA (as well as the J-shaped relationship in this group of patients).

75.

Zanchetti A. Blood pressure targets of antihypertensive treatment: up and down the J-shaped curve. Eur Heart J. 2010;31:2837–40.PubMedCrossRef

76.

Athyros VG, Hatzitolios AI, Karagiannis A, Savopoulos C, Katsiki N, Tziomalos K, Papagianni A, Kakafika A, Gossios TD, Mikhailidis DP, IMPERATIVE Collaborative Group. IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci. 2011;7(6):984–92.PubMedCrossRef

77.

Systolic Blood Pressure Intervention Trial (SPRINT). ClinicalTrials.gov Identifier: NCT01206062.

78.

Sethi A, Arora RR. Ambulatory blood pressure as a predictor of cardiovascular risk. Arch Med Sci. 2009;5:3–9.

79.

Stepien M, Banach M, Jankowski P, Rysz J. Clinical implications of non-invasive measurement of central aortic blood pressure. Curr Vasc Pharmacol. 2010;8:747–52.PubMedCrossRef

80.

Lai HM, Aronow WS, Mercando AD, Kalen P, Desai HV, Gandhi K, Sharma M, Amin H, Lai TM. Risk factor reduction in progression of angiographic coronary artery disease. Arch Med Sci. 2012;8(3):444–8.PubMedCrossRef

81.

Zanchetti A, Mancia G, Black HR, Oparil S, Waeber B, Schmieder RE, Bakris GL, Messerli FH, Kjeldsen SE, Ruilope LM. Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. J Hypertens. 2009;27:673–9.PubMedCrossRef

Title: Blood Pressure J-Curve: Current Concepts
Authors: Maciej Banach
Wilbert S. Aronow
Publication date: 01-12-2012
Publisher: Current Science Inc.
Published in: Current Hypertension Reports / Issue 6/2012
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-012-0314-3

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Blood Pressure J-Curve: Current Concepts

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2012

What Is the Optimal First-Line Agent in Children Requiring Antihypertensive Medication?

Mechanisms and Consequences of Inflammatory Signaling in the Myocardium

Hypertension and Mild Cognitive Impairment

Neurogenic Hypertension: Revelations from Genome-Wide Gene Expression Profiling

Ambulatory Blood Pressure Monitoring in Pediatric Renal Transplantation

Non-Communicable Disease: A Welcome and Long Needed Addition to the WHO’s 2012 World Heath Statistics

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page